These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

243 related items for PubMed ID: 34676402

  • 1. Xbp1s-Ddit3 promotes MCT-induced pulmonary hypertension.
    Jiang H, Ding D, He Y, Li X, Xu Y, Liu X.
    Clin Sci (Lond); 2021 Nov 12; 135(21):2467-2481. PubMed ID: 34676402
    [Abstract] [Full Text] [Related]

  • 2. Proteomic analysis reveals that Xbp1s promotes hypoxic pulmonary hypertension through the p-JNK MAPK pathway.
    Jiang H, Niu Y, He Y, Li X, Xu Y, Liu X.
    J Cell Physiol; 2022 Mar 12; 237(3):1948-1963. PubMed ID: 34964131
    [Abstract] [Full Text] [Related]

  • 3. Glycyrrhizin, inhibitor of high mobility group box-1, attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling in rats.
    Yang PS, Kim DH, Lee YJ, Lee SE, Kang WJ, Chang HJ, Shin JS.
    Respir Res; 2014 Nov 25; 15():148. PubMed ID: 25420924
    [Abstract] [Full Text] [Related]

  • 4. Exploration of the Notch3-HES5 signal pathway in monocrotaline-induced pulmonary hypertension using rat model.
    Chen X, Zhou W, Hu Q, Huang L.
    Congenit Heart Dis; 2019 May 25; 14(3):396-402. PubMed ID: 30811836
    [Abstract] [Full Text] [Related]

  • 5. Commentary on: Xbp1s-Ddit3, DNA damage and pulmonary hypertension.
    Lemay SE, Bonnet S, Potus F.
    Clin Sci (Lond); 2022 Jan 14; 136(1):163-166. PubMed ID: 35005770
    [Abstract] [Full Text] [Related]

  • 6. Resveratrol reverses monocrotaline-induced pulmonary vascular and cardiac dysfunction: a potential role for atrogin-1 in smooth muscle.
    Paffett ML, Lucas SN, Campen MJ.
    Vascul Pharmacol; 2012 Jan 14; 56(1-2):64-73. PubMed ID: 22146233
    [Abstract] [Full Text] [Related]

  • 7. Tetrandrine prevents monocrotaline-induced pulmonary arterial hypertension in rats through regulation of the protein expression of inducible nitric oxide synthase and cyclic guanosine monophosphate-dependent protein kinase type 1.
    Wang X, Yang Y, Yang D, Tong G, Lv S, Lin X, Chen C, Dong W.
    J Vasc Surg; 2016 Nov 14; 64(5):1468-1477. PubMed ID: 26527422
    [Abstract] [Full Text] [Related]

  • 8. Neutralization of CXCL12 attenuates established pulmonary hypertension in rats.
    Bordenave J, Thuillet R, Tu L, Phan C, Cumont A, Marsol C, Huertas A, Savale L, Hibert M, Galzi JL, Bonnet D, Humbert M, Frossard N, Guignabert C.
    Cardiovasc Res; 2020 Mar 01; 116(3):686-697. PubMed ID: 31173066
    [Abstract] [Full Text] [Related]

  • 9. Aloperine protects pulmonary hypertension via triggering PPARγ signaling and inhibiting calcium regulatory pathway in pulmonary arterial smooth muscle cells.
    Shan X, Gegentuya, Wang J, Feng H, Zhang Z, Zheng Q, Zhang Q, Yang K, Wang J, Xu L.
    Am J Physiol Cell Physiol; 2023 Oct 01; 325(4):C1058-C1072. PubMed ID: 37661916
    [Abstract] [Full Text] [Related]

  • 10. Chrysin Alleviates Monocrotaline-Induced Pulmonary Hypertension in Rats Through Regulation of Intracellular Calcium Homeostasis in Pulmonary Arterial Smooth Muscle Cells.
    Dong F, Zhang J, Chen X, Zhang S, Zhu L, Peng Y, Guo Z.
    J Cardiovasc Pharmacol; 2020 Jun 01; 75(6):596-602. PubMed ID: 32168153
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Interferon regulatory factor 7 inhibits rat vascular smooth muscle cell proliferation and inflammation in monocrotaline-induced pulmonary hypertension.
    Deng Y, Guo SL, Li JQ, Xie SS, Zhou YC, Wei B, Wang Q, Wang F.
    Life Sci; 2021 Jan 01; 264():118709. PubMed ID: 33152351
    [Abstract] [Full Text] [Related]

  • 14. [TRPC6 mediates the enhancements of pulmonary arterial tone and intracellular Ca2+ concentration of pulmonary arterial smooth muscle cells in pulmonary hypertension rats].
    Zhang MF, Liu XR, Yang N, Lin MJ.
    Sheng Li Xue Bao; 2010 Feb 25; 62(1):55-62. PubMed ID: 20179889
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Inhibition of Shp2 ameliorates monocrotaline-induced pulmonary arterial hypertension in rats.
    Cheng Y, Yu M, Xu J, He M, Wang H, Kong H, Xie W.
    BMC Pulm Med; 2018 Aug 07; 18(1):130. PubMed ID: 30086741
    [Abstract] [Full Text] [Related]

  • 18. Pioglitazone alleviates cardiac and vascular remodelling and improves survival in monocrotaline induced pulmonary arterial hypertension.
    Behringer A, Trappiel M, Berghausen EM, Ten Freyhaus H, Wellnhofer E, Odenthal M, Blaschke F, Er F, Gassanov N, Rosenkranz S, Baldus S, Kappert K, Caglayan E.
    Naunyn Schmiedebergs Arch Pharmacol; 2016 Apr 07; 389(4):369-79. PubMed ID: 26742933
    [Abstract] [Full Text] [Related]

  • 19. Selective activation of angiotensin AT2 receptors attenuates progression of pulmonary hypertension and inhibits cardiopulmonary fibrosis.
    Bruce E, Shenoy V, Rathinasabapathy A, Espejo A, Horowitz A, Oswalt A, Francis J, Nair A, Unger T, Raizada MK, Steckelings UM, Sumners C, Katovich MJ.
    Br J Pharmacol; 2015 May 07; 172(9):2219-31. PubMed ID: 25522140
    [Abstract] [Full Text] [Related]

  • 20. Pathophysiological roles of nuclear factor kappaB (NF-kB) in pulmonary arterial hypertension: effects of synthetic selective NF-kB inhibitor IMD-0354.
    Hosokawa S, Haraguchi G, Sasaki A, Arai H, Muto S, Itai A, Doi S, Mizutani S, Isobe M.
    Cardiovasc Res; 2013 Jul 01; 99(1):35-43. PubMed ID: 23631839
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.